News in Brief
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
medicine and life sciences
Modified CRISPR-Cas9 gene editing scissors are enabling researchers at UZH to make alterations to the genetic material of single-cell organisms that are indistinguishable from natural mutations. This method is making it possible to develop a (harmless) experimental live vaccine for the widespread parasite Toxoplasma gondii.
From a research hypothesis in experimental biology to the possible application in the field of anticancer therapies, through computer simulations. This is the essential course of an interdisciplinary and international research project that has identified the mechanisms by which particular peptides can penetrate cell membranes and contribute to the elimination of tumors. The study, conducted by the University of Lausanne and involving the research group in computational biophysics of the Dalle Molle Institute of USI and SUPSI, has been published in the prestigious scientific journal PNAS.
Selected Jobs
Open Rank Assistant Professor with Tenure Track or Extraordinary Professor for Medical Oncology ( focus on "Gynecological Oncology") University of Bern
PHD Position in Organoid Handling (m/f), 100% Centre Suisse d’Electronique et de Microtechnique, Alpnach Dorf
Responsable du groupe de recherche «Amélioration des plantes de grandes cultures et ressources génétiques» Agroscope, Nyon
Forschungsgruppenleiter/in Ackerpflanzenzüchtung und Genressourcen Agroscope, Nyon
PhD Position in Intelligent Health Systems (Explainable Intelligent Agents) University of Applied Sciences and Arts Western Switzerland (HES-SO)
Last job offers
News in Brief
Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene